Skip to content

pierrot harvie

  • Ph.D.
  • Associate Director of Formulation
  • PhaseRx Inc
  • 15h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 992CitationsNumber of citations received by pierrot's publications. Updated daily.

Recent publications

  • Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs

    • Vaish N
    • Chen F
    • Seth S
    • et al.
    N/AReaders
    59Citations
    Get full text
  • Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles.

    • Harvie P
    • Wong F
    • Bally M
    N/AReaders
    N/ACitations
    Get full text

Professional experience

Associate Director of Formulation

PhaseRX

March 2013 - Present

Sr Research Scientist

Marina biotech (Formerly MDRNA inc)

January 2007 - July 2012(6 years)

Scientist

Celator pharmaceutical

July 2003 - October 2006(3 years)

Scientsit

Targeted Genetics Corporation

November 1999 - February 2003(3 years)

Education

Ph.D.

Université Laval - Laval University

September 1993 - May 1996(3 years)

Research interests

About

• More than Ten years experience working with drug delivery systems. • Expertise in delivering siRNA, miRNA, plasmid DNA and small molecules with liposomes and nanoparticles • Expertise with lipid, polymer, peptide, poly-cation, and pH sensitive polymer as drug delivery system. • Strong technical knowledge and practical skills in most of the biophysical, biological as well as the molecular biology techniques generally used to characterize drug and gene delivery systems. • Solid background in preclinical pharmacology and toxicity, and experience in the evaluation of drug delivery systems for anti-tumor activity. • Experience with process development technique and knowledge of GMP manufacturing regulation. • Proficient in most of the virological, and immunological techniques and experience in histopathology analysis, with respect to disease progression to evaluate drug efficacy or toxicity.

Co-authors (82)

Other IDs